These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 25865849)
1. Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. Markowski MC; Pienta KJ Asian J Androl; 2015; 17(6):936-8; discussion 938. PubMed ID: 25865849 [TBL] [Abstract][Full Text] [Related]
2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
3. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364 [TBL] [Abstract][Full Text] [Related]
5. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318 [TBL] [Abstract][Full Text] [Related]
6. [Monitoring of treatment for metastatic castration-resistant prostate cancer]. Hinz S Aktuelle Urol; 2017 May; 48(3):225-229. PubMed ID: 28614883 [TBL] [Abstract][Full Text] [Related]
7. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment. Bahl A Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207 [TBL] [Abstract][Full Text] [Related]
8. Treatment sequencing in metastatic castrate-resistant prostate cancer. Sartor O; Gillessen S Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials. Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850 [TBL] [Abstract][Full Text] [Related]
10. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882 [TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; Mucciarini C; Zustovich F; Macrini S; Burgio SL; Santarossa S; D'Aniello C; Basso U; Tarasconi S; Cortesi E; Buttigliero C; Ruatta F; Veccia A; Conteduca V; Maines F; Galligioni E Eur Urol; 2015 Jul; 68(1):147-53. PubMed ID: 25457020 [TBL] [Abstract][Full Text] [Related]
12. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646 [TBL] [Abstract][Full Text] [Related]
13. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425 [TBL] [Abstract][Full Text] [Related]
14. [Bone and calcium metabolism associated with malignancy. Bone metastasis of prostate cancer:overview of clinical features and treatments.]. Suzuki K; Miyazawa Y Clin Calcium; 2018; 28(11):1441-1449. PubMed ID: 30373999 [TBL] [Abstract][Full Text] [Related]
15. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Badrising SK; van der Noort V; Hamberg P; Coenen JL; Aarts MJ; van Oort IM; van den Eertwegh AJ; Los M; van den Berg HP; Gelderblom H; Vrijaldenhoven S; Kerver ED; van Voorthuizen T; de Jong IJ; Haanen JB; Bergman AM; Oncology; 2016; 91(5):267-273. PubMed ID: 27544669 [TBL] [Abstract][Full Text] [Related]
17. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. Payne H; Bahl A; Mason M; Troup J; De Bono J BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837 [TBL] [Abstract][Full Text] [Related]
18. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
19. [Review on quality of life in CRPC patients]. Miller K Aktuelle Urol; 2017 May; 48(3):219-224. PubMed ID: 28614882 [TBL] [Abstract][Full Text] [Related]
20. [How to manage patients with CRPC?]. Beuzeboc P; Massard C Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]